The role of Corporate Venture Capital funds in financing biotechnology and healthcare: differing approaches and performance consequences Online publication date: Fri, 31-Jul-2009
by James Henderson
International Journal of Technoentrepreneurship (IJTE), Vol. 2, No. 1, 2009
Abstract: Corporate Venture Capital (CVC) is an alternative financing mechanism to traditional venture capital for promising start-ups. Yet, these programmes have been operated in very different ways with some focusing on ''reserving the right to play'' vs. others focusing on ''leveraging or upgrading the core''. The paper explores the role of these different CVC models and assesses the performance consequences for the start-ups. Existing research has found that CVC programmes that focused on ventures related to their base businesses were more likely to have more initial public offerings and higher valuations than independent venture capitalists. Furthermore, researchers have found that this effect may be owing to corporate endorsement or the relationships actually developed between the business unit and the entrepreneurial venture. This paper confirms these findings for the biotechnology context.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Technoentrepreneurship (IJTE):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com